腹针治疗非典型抗精神病药物所致肥胖的治疗效果观察

doi:10.3969/j.issn.1006-7795.2020.01.015

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (1): 75-79.doi: 10.3969/j.issn.1006-7795.2020.01.015

• 精神疾病中西医结合治疗 • 上一篇下一篇

腹针治疗非典型抗精神病药物所致肥胖的治疗效果观察

李雪^1,2, 朱虹^1,2, 房萌^1,2, 宁艳哲^1,2, 赵爽^1,2, 尹冬青^1,2

1. 首都医科大学附属北京安定医院国家精神心理疾病临床研究中心精神疾病诊断与治疗北京市重点实验室, 北京 100088;
2. 首都医科大学人脑保护高精尖创新中心, 北京 100069

收稿日期:2019-12-01 出版日期:2020-02-21 发布日期:2020-02-13
通讯作者: 尹冬青 E-mail:yindq1123@163.com
基金资助:
北京市中医药科技发展基金项目（JJ 2018-42，QN2018-26），首都卫生发展科研专项重点攻关项目（2018-1-2122），北京市属医院科研培育计划项目（PZ2019033），北京市医院管理中心"登峰"计划（DFL20191901）。

Clinical observation of abdominal acupuncture in the treatment of obesity caused by atypical antipsychotics

Li Xue^1,2, Zhu Hong^1,2, Fang Meng^1,2, Ning Yanzhe^1,2, Zhao Shuang^1,2, Yin Dongqing^1,2

1. The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China;
2. Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100069, China

Received:2019-12-01 Online:2020-02-21 Published:2020-02-13
Supported by:
This study was supported by Chinese Medicine Science and Technology Development Found of Beijing (JJ 2018-42,QN2018-26),Capital Health Research and Development of Special Founding(2018-1-2122), Scientific Research and Cultivation Fund of Beijing Hospital Management Center(PZ2019033), Beijing Hospitals Authority' Ascent Plan (DFL20191901).

摘要/Abstract

摘要： 目的探讨腹针对非典型抗精神病药物所致肥胖患者体质量、腰围、体质量指数（body mass index，BMI）及血脂的影响。方法将60例服用非典型抗精神病药物所致肥胖的患者，根据年龄、性别、病程、既往肥胖时间，按组间均衡的原则分为治疗组和对照组，每组30例。治疗组采用腹针治疗，对照组为健康指导。观察两组患者在治疗前、治疗第28天和治疗第56天体质量、腰围、BMI及血脂浓度的变化。结果对研究结果采用重复多因素方差分析，治疗组腰围、BMI、三酰甘油与对照组相比，差异有统计学意义（P < 0.05），治疗组效果优于对照组。进行两两比较分析结果发现，在治疗第28天时，治疗组腰围及BMI与对照组相比，差异有统计学意义（P < 0.05）；第56天时，治疗组体质量、腰围、BMI、三酰甘油与对照组相比，差异有统计学意义（P < 0.05），治疗组效果优于对照组。结论腹针能有效地降低服用抗精神病药物所致肥胖患者体质量、腰围、BMI，促进脂代谢，降低血脂水平。

关键词: 腹针, 非典型抗精神病药, 肥胖, 脂代谢

Abstract: Objective To investigate the effects of abdominal acupuncture on body weight, waist circumference, body mass index (BMI), and blood lipids in obese patients with atypical antipsychotics.Methods Sixty patients with obesity caused by atypical antipsychotics were divided into a treatment group (30 cases) and a control group (30 cases). The treatment group was treated with abdominal acupuncture, while the control group with health guidance. The changes of body weight, waist circumference, BMI and blood lipid levels of patients in the two groups before treatment were observed, on the 28th day and on the 56th day.Results Repeated multivariate analysis of variance was used to study the results. The results showed that the time effects and grouping effects on weight, waist circumference, BMI, cholesterol and triglycerides were significantly interactive (P<0.05). Further analysis indicated that the waist circumference and BMI data on the 28th day of treatment were better than the control group (P<0.05). On the 56th day, the weight, waist circumference, BMI, and triglyceride data of the treatment group were better than the control group (P<0.05), with the statistically significant difference. Conclusion Abdominal acupuncture can decrease the body weight, BMI, and lipid metabolism of obese patients with antipsychotics.

Key words: abdominal acupuncture, atypical antipsychotics, obese patients, lipid metabolism

中图分类号:

R749.3

李雪, 朱虹, 房萌, 宁艳哲, 赵爽, 尹冬青. 腹针治疗非典型抗精神病药物所致肥胖的治疗效果观察[J]. 首都医科大学学报, 2020, 41(1): 75-79.

Li Xue, Zhu Hong, Fang Meng, Ning Yanzhe, Zhao Shuang, Yin Dongqing. Clinical observation of abdominal acupuncture in the treatment of obesity caused by atypical antipsychotics[J]. Journal of Capital Medical University, 2020, 41(1): 75-79.

参考文献

[1] 刘生,王高华,王惠玲.抗精神病药物治疗所致药源性肥胖与2型糖尿病的关系[J].国际精神病学杂志,2008(3):176-179.
[2] Mitchell A J,Vancampfort D,De Herdt A,et al. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia?A comparative meta-analysis of first episode,untreated and treated patients[J]. Schizophr Bull,2013,39:295-305.
[3] 陈春明,孔灵芝.中国成人超重和肥胖症预防控制指南[M]北京.人民卫生出版社,2006,4.
[4] World Health Organization. The ICD-10 classification of mental and behavioural disorders. Clinical description and diagnostic guideline[M]. Geneva:World Health Organization,1992:8.
[5] Leucht S,Corves C,ArbterD,et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia:a meta-analysis[J].Lancet,2009,373(9657):31-41.
[6] Henderson D C,Cagliero E,Cray C,et al. Clozapine,diabetes mellitus,weight gain,and lipid abnormalities:a five-year naturalistic study[J]. Am J Psychiat,2000,157(6):975-978.
[7] Patel J K,Buckley P F,Woolson S,et al. Metabolic profiles of second-generation antipsychotics in early psychosis:findings from the CAFE study[J]. Schizophr Res,2009,111(1-3):9-16.
[8] Hwang Y J,Dixon S N,Reiss J P,et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults:a population-based cohort study[J]. Ann Intern Med,2014,161(4):242-248.
[9] 赵帅,周晓琴,夏海龙,等.住院精神分裂症患者心血管疾病发生风险研究[J].中国神经精神疾病杂志,2017,43(9):539-543.
[10] OLfson M,Gerhard T,Huang C,et al. Premature mortality among adults with schizophrenia in the United States[J]. JAMA Psychiat,2015,72(12):1172-1181.
[11] Nicole E M,Chantel K,Sri M A,et al. Antipsychotics,metabolic adverse effects,and cognitive function in schizophrenia[J]. Front Psychiat,2018,5(9):622.
[12] Raben A T,Marshe V S,Chintoh A,et al. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits:a systematic review and implications for treatment[J]. Front Neurosci,2017,11:741.
[13] Haffner S M. The metabolic syndrome:inflammation,diabetes mellitus,and cardiovascular disease[J]. Am J Cardiol,2006,97(2A):3A-11A.
[14] Chen P Y,Huang M C,Chiu C C,et al. Association of plasma reti-nol-binding protein-4,adiponectin,and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia[J]. Pro Neuropsychopharmacol Bio-Psychiat,2011,35(8):1927-1932.
[15] Bae Y J,Kim S H,Chung J H,et al. Evaluation of adiposity-related biomarkers as metabolic syndrome indicators[J]. Clin Nutr Res, 2013,2:91-99.
[16] 薄智云.腹针疗法[M].北京:中国科学技术出版社,1999:46-67,92-93.
[17] 杨礼泛,黄龙坚,吕艳,等.腹针治疗单纯性肥胖临床疗效Meta分析[J].中医临床研究,2015,7(31):1-4.
[18] 张蕾,丁瑛,张丽娜,等.腹针对奥氮平所致肥胖脂代谢的影响[J].中国针灸,2017,37(6):591-593
[19] 蔡荣林,管媛媛,武红利,等.胃俞募配穴针刺与胃俞、中脘单穴针刺对健康受试者胃扩张状态下静息态脑功能局部一致性的影响[J].中国针灸,2018,38(4):379-385.

腹针治疗非典型抗精神病药物所致肥胖的治疗效果观察

Clinical observation of abdominal acupuncture in the treatment of obesity caused by atypical antipsychotics

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张莹, 刘超楠, 时红林, 刘芳, 陈德喜, 时红波. P53凋亡刺激蛋白2介导酒精性肝病脂代谢相关基因的转录组学分析[J]. 首都医科大学学报, 2023, 44(1): 85-92.
[2]	张瑾, 池晶晶, 张蕊, 张小燕, 白文佩. 孕前肥胖及超重女性的孕期管理模式探讨及肥胖相关胎盘因子分析[J]. 首都医科大学学报, 2022, 43(5): 774-781.
[3]	修双玲, 付俊玲, 穆志静, 孙丽娜, 赵蕾. 老年2型糖尿病患者体脂率对肌力和躯体功能的影响[J]. 首都医科大学学报, 2022, 43(4): 641-646.
[4]	苗祖霈, 张迎花, 肖克令, 司瑾, 张浩宇, 李静. 肥胖程度对急性ST段抬高型心肌梗死患者预后的影响[J]. 首都医科大学学报, 2022, 43(2): 192-198.
[5]	李健, 白文佩, 江波, 白栎然, 吴凤云. 生酮饮食对超重/肥胖多囊卵巢综合征女性月经及生育力的影响[J]. 首都医科大学学报, 2021, 42(6): 1021-1025.
[6]	王虎生, 阮祥燕, 程姣姣, Alfred O. Mueck. 肥胖型多囊卵巢综合征的氧化应激与脂代谢关系的研究[J]. 首都医科大学学报, 2021, 42(4): 540-546.
[7]	李健, 吴凤云, 张能维, 廉东波, 樊庆, 许光中, 杜德晓, 孙志鹏, 杜燕敏, 白文佩. 微创减重手术对重度肥胖女性月经周期及生育功能的影响[J]. 首都医科大学学报, 2021, 42(2): 200-203.
[8]	张露平, 阮祥燕, 鞠蕊, 秦爽, 王宾红, 许新, 杨瑜, Alfred O. Mueck. 围绝经期及绝经后女性基于腰椎定量电子计算机断层扫描测定的内脏脂肪与糖脂代谢的相关性[J]. 首都医科大学学报, 2020, 41(4): 508-513.
[9]	闵敏, 阮祥燕, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型多囊卵巢综合征患者代谢综合征及其组分的影响[J]. 首都医科大学学报, 2020, 41(4): 514-519.
[10]	卢晶, 李奇, 朱晓蓉, 谢荣荣, 杨金奎. KCNH6基因肝脏特异性敲除小鼠的构建及其初步应用[J]. 首都医科大学学报, 2020, 41(1): 8-13.
[11]	苏万春, 孙宇光, 夏松, 信建峰, 常鲲, 沈文彬. 体质量指数与下肢继发性淋巴水肿预后的分析[J]. 首都医科大学学报, 2019, 40(6): 938-942.
[12]	闵敏, 阮祥燕, 赵越, 王虎生, 程姣姣, 罗穗豫, 许仲婷, 李萌, 张露平, 王月姣, Alfred O. Mueck. 奥利司他综合干预对超重或肥胖型PCOS患者雄激素及糖脂代谢的影响[J]. 首都医科大学学报, 2019, 40(4): 572-577.
[13]	张怡尘, 曹曦, 杨金奎. G蛋白偶联受体MAS对肝脏糖脂代谢的影响[J]. 首都医科大学学报, 2019, 40(3): 409-416.
[14]	金婧, 阮祥燕, 华琳, 李杨璐, 王利娟, 王虎生, 赵越, Alfred O. Mueck. 多囊卵巢综合征卵巢储备功能降低患者肥胖及糖脂代谢特征[J]. 首都医科大学学报, 2018, 39(4): 505-511.
[15]	鹿星梦, 信中. Ang(1-7)通过调节内质网应激改善骨骼肌脂代谢及胰岛素抵抗[J]. 首都医科大学学报, 2018, 39(4): 532-536.